BRT offers in vitro approaches for evaluating skin sensitization across key events of the adverse outcome pathway, including regulatory and emerging New Approach Methodologies (NAMs).
In vitro approaches addressing the molecular initiating event associated with skin sensitization.
In vitro approaches evaluating keratinocyte activation associated with the skin sensitization response.
In vitro approaches evaluating dendritic cell activation associated with the skin sensitization response.
BRT offers an in vitro approach for evaluating skin sensitization associated with medical devices.
BRT supports defined approaches (DA) and integrated approaches to testing and assessment (IATA) that combine and interpret data from multiple NAM sources to support skin sensitization assessment.
BRT has participated as a test site in national and international validation efforts supporting the advancement of in vitro methods for skin sensitization assessment.
BRT works with clients to develop customized in vitro skin sensitization studies based on specific research objectives, test articles, methods, and endpoints.
